Emtricitabine and tenofovir disoproxil fumarate
- Generic Name
- Emtricitabine and tenofovir disoproxil fumarate
- Indication
适用于与其他抗逆转录病毒药物联用，治疗成人和12岁（含）以上儿童的 HIV-1感染。
SCOPE: Strategies to Combine PrEP With Prevention Efforts
- First Posted Date
- 2013-04-16
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- FHI 360
- Registration Number
- NCT01832571
- Locations
- 🇰🇪
Sex Workers Outreach Programme (SWOP), Nairobi, Kenya
🇰🇪Family Health Options Kenya, Eldoret, Kenya
A Pilot Study on Raltegravir, Tenofovir and Emtricitabine for Peri-exposure Prophylaxis for HIV Infection
- First Posted Date
- 2012-10-02
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Projeto Praça Onze
- Target Recruit Count
- 65
- Registration Number
- NCT01697046
- Locations
- 🇧🇷
Monica Barbosa de Souza, Rio de Janeiro, RJ, Brazil
A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
- Conditions
- HIV-1 Infection
- Interventions
- Drug: Second line ART regimens - based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)Drug: Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & availableOther: SOC adherence versus SOC+CPI adherence
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2019-03-15
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 545
- Registration Number
- NCT01641367
- Locations
- 🇧🇷
Hospital Nossa Senhora da Conceicao CRS (12201), Porto Alegre, RS, Brazil
🇧🇷Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇮🇳Chennai Antiviral Research and Treatment (CART) CRS (11701), Chennai, Taramani, India
Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected
- Conditions
- HIV-1 InfectionPf Subclinical Parasitemia
- Interventions
- Drug: Trimethoprim/sulfamethoxazole
- First Posted Date
- 2012-07-03
- Last Posted Date
- 2019-08-06
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 52
- Registration Number
- NCT01632891
- Locations
- 🇰🇪
AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601), Eldoret, Kenya
🇰🇪Walter Reed Project - Kenya Med. Research Institute Kericho CRS (12501), Kericho, Kenya
🇲🇼College of Med. JHU CRS (30301), Blantyre, Malawi
A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2012-07-02
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 342
- Registration Number
- NCT01632345
On Demand Antiretroviral Pre-exposure Prophylaxis for HIV Infection in Men Who Have Sex With Men
- First Posted Date
- 2011-11-17
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- ANRS, Emerging Infectious Diseases
- Target Recruit Count
- 400
- Registration Number
- NCT01473472
- Locations
- 🇫🇷
CHU Hôtel Dieu, Nantes, France
🇫🇷Hôpital de l'Archet, Nice, France
🇫🇷Hôpital Gustave Dron, Tourcoing, France
Trial To Assess The Lipid-Lowering Effect Of Adding Tenofovir/Emtricitabine Co-Formulation Vs Placebo To Hiv-1-Infected Subjects With Dyslipidemia And Sustained Viral Load Suppression Under Monotherapy With Ritonavir-Boosted Protease Inhibitors
- Conditions
- HIVDyslipidemia
- Interventions
- First Posted Date
- 2011-10-25
- Last Posted Date
- 2014-06-19
- Lead Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
- Target Recruit Count
- 48
- Registration Number
- NCT01458977
- Locations
- 🇪🇸
Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain
🇪🇸Hospital Valle Hebrón, Barcelona, Spain
🇪🇸Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain
A Key Link for Transmission Prevention
- Conditions
- HIV
- Interventions
- Behavioral: Standard HIV prevention messages
- First Posted Date
- 2011-10-12
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 46
- Registration Number
- NCT01450189
- Locations
- 🇲🇼
Lighthouse Trust, Kamuzu Central Hospital, Lilongwe, Malawi
🇲🇼UNC Project, Lilongwe, Malawi
REMEMBER: Reducing Early Mortality & Morbidity by Empiric Tuberculosis (TB) Treatment
- Conditions
- HIV Infection
- Interventions
- Drug: Rifampin/isoniazid/pyrazinamide/ethambutol FDCDrug: Rifampin/isoniazid FDC
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 851
- Registration Number
- NCT01380080
- Locations
- 🇮🇳
BJ Medical College CRS, Pune, Maharashtra, India
🇮🇳YRG CARE Medical Ctr., VHS Chennai CRS, Rajiv Gandhi Salai Taramani, Chennai, India
🇭🇹GHESKIO Institute of Infectious Diseases and Reproductive Health (GHESKIO - IMIS) CRS, Port Au Prince, Haiti
Study of Options for Second-Line Effective Combination Therapy (SELECT)
- Conditions
- HIV-1 Infection
- Interventions
- Drug: Abacavir/lamivudine/zidovudineDrug: Abacavir/lamivudine
- First Posted Date
- 2011-05-12
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
- Target Recruit Count
- 515
- Registration Number
- NCT01352715
- Locations
- 🇧🇷
Instituto de Pesquisa Clinica Evandro Chagas (12101), Rio de Janeiro, Brazil
🇲🇼University of North Carolina Lilongwe CRS (12001), Lilongwe, Malawi
🇿🇦Soweto ACTG CRS (12301), Johannesburg, South Africa
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.